The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers
Open accessAbstract
Lipids in the brain are major components playing structural functions as well as physiological roles in nerve cells, such as neural communication, neurogenesis, synaptic transmission, signal transduction, membrane compartmentalization, and regulation of gene expression. Determination of brain lipid composition may provide not only essential information about normal brain functioning, but also about changes with aging and diseases. Indeed, deregulations of specific lipid classes and lipid homeostasis have been demonstrated in neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Furthermore, recent studies have shown that membrane microdomains, named lipid rafts, may change their composition in correlation with neuronal impairment. Lipid rafts are key factors for signaling processes for cellular responses. Lipid alteration in these signaling platforms may correlate with abnormal protein distribution and aggregation, toxic cell signaling, and other neuropathological events related with these diseases. This review highlights the manner lipid changes in lipid rafts may participate in the modulation of neuropathological events related to AD and PD. Understanding and characterizing these changes may contribute to the development of novel and specific diagnostic and prognostic biomarkers in routinely clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In this sense, during the last decades, the amyloid cascade hypothesis [57] has been the most accepted scenario to explain the pathogenic processes of AD.”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095 · cited 1×
“It is widely accepted that cholesterol synthesis is very high in the developing brain, but this rate declines at low and constant levels during adulthood [35].”
BackgroundImmunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation
Galvagnion, C., Buell, A. K., Meisl, G., Michaels, T. C. T., Vendruscolo, M., Knowles, T. P. J., & Dobson, C. M. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1750 · Cited by 661
Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis
Broen, M. P. G., Narayen, N. E., Kuijf, M. L., Dissanayaka, N. N. W., & Leentjens, A. F. G. (2016) · Movement Disorders · doi:10.1002/mds.26643 · Cited by 457 · cited 2×
“During the course of the disease, the patients suffer motor symptoms such as muscle rigidity, bradykinesia, rest tremor and postural and gait impairment [117].”
BackgroundHan, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429
The chemistry of Alzheimer’s disease
Rauk, A. (2009) · Chemical Society Reviews · doi:10.1039/b807980n · Cited by 417 · cited 1×
“At the molecular level, β-amyloid peptide (Aβ), and tau protein have been identify as the main agents causing Alzheimer’s disease [56].”
BackgroundMitchell, R. W., On, N. H., Del Bigio, M. R., Miller, D. W., & Hatch, G. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07245.x · Cited by 337 · cited 2×
“There are two prevailing hypotheses: (i) passive diffusion using a “flip-flop” mechanism independent of proteins [10–12] and (ii) protein-mediated transport mechanisms using specific fatty acid transport proteins, including caveolin-1 [13], intracellular fatty acid binding proteins 1–9 (FABP), and plasma membrane fatt…”
BackgroundShinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., Waichunas, D., Bumgarner, L., Bourdette, D., Silbert, L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130722 · Cited by 288
Effects of membrane lipids on ion channel structure and function
Tillman, T. S., & Cascio, M. (2003) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:38:2:161 · Cited by 265
Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers
Wong, M. W., Braidy, N., Poljak, A., Pickford, R., Thambisetty, M., & Sachdev, P. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.008 · Cited by 223 · cited 14×
“Indeed, DHA levels reach 15−50% of total fatty acids in neurons.”
BackgroundInfluentialCerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209
Ben Gedalya, T., Loeb, V., Israeli, E., Altschuler, Y., Selkoe, D. J., & Sharon, R. (2009) · Traffic · doi:10.1111/j.1600-0854.2008.00853.x · Cited by 169
ApoE4 upregulates the activity of mitochondria‐associated ER membranes
Tambini, M. D., Pera, M., Kanter, E., Yang, H., Guardia‐Laguarta, C., Holtzman, D., Sulzer, D., Area‐Gomez, E., & Schon, E. A. (2016) · The EMBO Reports · doi:10.15252/embr.201540614 · Cited by 166
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141
Functional and Structural Benefits Induced by Omega-3 Polyunsaturated Fatty Acids During Aging
Cutuli, D. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160614091311 · Cited by 139
Lipids in the nervous system: From biochemistry and molecular biology to patho-physiology
Cermenati, G., Mitro, N., Audano, M., Melcangi, R. C., Crestani, M., De Fabiani, E., & Caruso, D. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.011 · Cited by 137
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121
Internalization of β-Amyloid Peptide by Primary Neurons in the Absence of Apolipoprotein E
Saavedra, L., Mohamed, A., Ma, V., Kar, S., & de Chaves, E. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701823200 · Cited by 118
van Dijk, K. D., Persichetti, E., Chiasserini, D., Eusebi, P., Beccari, T., Calabresi, P., Berendse, H. W., Parnetti, L., & van de Berg, W. D. J. (2013) · Movement Disorders · doi:10.1002/mds.25495 · Cited by 101
Scheff, S. W., Ansari, M. A., & Mufson, E. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.030 · Cited by 100 · cited 2×
“Interestingly, plasma concentrations of MDA were even more elevated in patients with mild cognitive impairment (MCI) than in AD subjects or healthy controls [175,176] as an indicative of the high lipid peroxidation scenario in early stages of this neuropathology.”
BackgroundHarari, O., Cruchaga, C., Kauwe, J. S. K., Ainscough, B. J., Bales, K., Pickering, E. H., Bertelsen, S., Fagan, A. M., Holtzman, D. M., Morris, J. C., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.032 · Cited by 82
The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Penke, B., Paragi, G., Gera, J., Berkecz, R., Kovács, Z., Crul, T., & VÍgh, L. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180911151716 · Cited by 55 · cited 1×
“Further, sphingolipids have a relevant role as precursor of lipid mediators and contribute to structural integrity of structural microdomains in neuronal membranes [20].”
BackgroundMembrane raft domains and remodeling in aging brain
Colin, J., Gregory-Pauron, L., Lanhers, M.-C., Claudepierre, T., Corbier, C., Yen, F. T., Malaplate-Armand, C., & Oster, T. (2016) · Biochimie · doi:10.1016/j.biochi.2016.08.014 · Cited by 55
Cited by
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
Husain, M. A., Laurent, B., & Plourde, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.630502 · Cited by 353
Díaz, M., Mesa-Herrera, F., & Marín, R. (2021) · Antioxidants · doi:10.3390/antiox10060907 · Cited by 84
Self-citationSphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80
Bai, X., Mai, M., Yao, K., Zhang, M., Huang, Y., Zhang, W., Guo, X., Xu, Y., Zhang, Y., Qurban, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01338-3 · Cited by 51
Metadata
- Authors
- Mesa-Herrera, F., Taoro-González, L., Valdés-Baizabal, C., Diaz, M., & Marín, R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-08-04
- Volume
- 20
- Issue
- 15
- Pages
- 3810
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2965146728
- Cited by
- 176
- References
- 31
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.